Manufacturer
APOTEX INC
Contents
Imatinib
Indication
Chronic myeloid leukaemia, Acute lymphoblastic leukaemia; Monotherapy in relapsed or refractory acute lymphoblastic leukaemia, Unresectable, metastatic GI stromal tumours, Hypereosinophilic syndrome,Myelodysplastic disease, Mastocytosis and Dermatofibrosarcoma protuberans
Instruction
Should be taken with food. Chronic myeloid leukaemia Chronic phase: 400 mg/day, up to 600 mg/day or 400 mg bid if needed. Blast crisis or accelerated phase: 600 mg/day, up to 400 mg bid if required. Acute lymphoblastic leukaemia; Monotherapy in relapsed or refractory acute lymphoblastic leukaemia 600 mg/day w/ induction, consolidation or maintenance therapy. Unresectable, metastatic GI stromal tumours 400 mg/day up to 400 mg bid. Hypereosinophilic syndrome 400 mg/day. Start w/ 100 mg/day in patients w/ FIP1L1-PDGF-α fusion kinase. Myelodysplastic disease 400 mg/day. Mastocytosis 400 mg/day. Start w/ 100 mg/day if there is associated eosinophilia. Dermatofibrosarcoma protuberans 400 mg bid.
Drug interaction
Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.
Malaysia
